Member Info for Sangijuelas1

A trial was set up and IND registered. The record has not been amended to reflect the new trial design.

The trial protocol including dose escalation has been ripped up and they are now going to dose with 5mg

One excuse after another to explain why 0 trials are running.

And no the 1 patient in the MS does not count as that will just produce an anecdote rather than any significant data.

Why do you think other companies do trials in multiple participants? I guess they must all be doing it wrong!

You really haven't seen the safety data from the IV trials a few years back with Foralumab,have you?

And you certainly haven't seen the trial data from the study in healthy volunteers as the only evidence of it is the claims made in Tils RNS

I am not trying to get through to you Cloudy as you are too far down the rabbit hole or a paid PR shill

5 days safety data isn't worth anything to anyone.

It would have been set at 14 days for a reason. The safety data for the Provention Bio anti cd3 drug was 14 days on IV

Because you need to get data on the cumulative effect of Foralumab over time.

And any signals of clinical bene?t are unlikely to show in such a short time frame.

Did they really not take Covid into account when they designed the trial?

Crikey they really are ****ing with you.

So the original plan was to dose with 5mg pills in an inpatient setting for 14 days to get safety data.

Given that Foralumab had severe adverse effects when it was originally given on IV that makes sense.

Now its just 5 days worth of safety data they are looking for in an at home setting.

What is the point? They agreed 14 days with FDA to demonstrate safety. Now they want to get the same safety data with 5 days not 14 with the same dose.

Absolute BS. How do they expect investors to keep falling for this nonsense.

Always another excuse, always another failure.

What's going on with the Covid trial?

I had always assumed the short bias too but you do see algo buys as well either attracted by buying activity or short trimming.

There is likely more than 1 algo program involved.

The auto trades are not Oliveira.

They feed into his sells. So when he is selling and no one is buying it triggers them to follow the momentum as per their algo program.

The algo trades have been going on for 2 years or so and started when 4D first listed on the US OTC market prior to Nasdaq.

OTC is primarily a mechanism to help with liquidity thru MMs but can be abused by short sellers

Clearly smart enough to spot a diamond in the rough

Nope there are still chunky sells going through on a frequent basis as there have been since he started in September
He is still selling but he is able to do so at the moment without crashing the price as someone is picking them up

And probably another 500k this week

Was that Angle cos it happened there as well?

Someone has been steadily buying all week

Looks like going to be a while.

Whose idea was it to add endpoints to the trial for Long Covid to be measured at days 60 and 90.

That's going to slow things down quite a bit

Good interview with DP from late 2020

https://themedicinemaker.com/manufacture/a-living-elixir/amp.html

This was Duncan 18 months ago talking about phenomenal results from Part A of the Keytruda trial

Imagine what he will be like when they bring out the update later this quarter

https://www.proactiveinvestors.co.uk/companies/amp/news/927610

Biden has been talking about the need for a cancer moonshot again today.

More funding into promising new therapies and treatment tools

Biden is out again today with talk of the cancer moonshot plan which means throwing a lot of money at promising new therapies and kicking the FDA up the butt

Of a top drawer young British biotech
Micro RX platform with 9 drug candidates in pipeline discovered in 7 years

Blautix ready for P3 and talk of commercial manufacture in a US market conservatively estimated to be worth $2.4bn.

Partnerships in place with 2 mega pharmas in MSD and Pfizer and a mid market one Merck Kgaa

Massive opportunity for 0518 as combination therapy with other treatments including immune checkpoint inhibitors $56bn market. Next ICI collaboration likely to require upfront payment if the pharma wants to play with 0518.

Collaborations with top cancer research settings like MD Anderson and Imperial college.

Forthcoming trial for Parkinsons with a seat on the science advisory board of Michael J Fox Foundation and partnership with Parkinsons UK. Both collaborations will make patient recruitment a lot easier.

Funding in place until the end of 2022

Incredibly experienced board with heavyweights like Axel Glasmacher and Katrin Rupalla (check out their CVs)

Directors DP and AS own 10% of the company including further investments in the last placing at 110p

Vaccines collaboration with MSD with milestone payments potentially available of up to $1bn

A second generation oncology drug in pre clinical development already recognised for potential to make CAR-T therapies work in solid tumours (holy grail)

Manufacturing capacity in place for commercial production with 7 years worth of accumulated experience and expertise

With 2 partnerships in place with MSD and them owning nearly 5% surely the inevitable will be only a matter of time

Yep at the last placing there were director buys and Merck buying at 110p

Price destroyed by firesale by forced seller

Company going from strength to strength

And waiting for Q1 cancer trial results

Following the momentum as some chunky buys today or short closing?

There was definitely a reluctance with the Oliveira sells this morning. Nothing under 37p and now there's been someone picking quite a few up they have dumped a few.

Think 37p is a clear bottom

4D investors have given up. Good job the company hasn't